Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

28 avr. 2026 10h14 HE | Source: ALK Abello

Invitation til præsentation af ALK’s regnskab for første kvartal 2026 tirsdag den 5. maj 2026

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) offentliggør delårsrapport for de første tre måneder af 2026 (Q1) om morgenen tirsdag den 5. maj 2026. ALK afholder senere samme dag kl. 13.30 (CEST) en...
28 avr. 2026 10h14 HE | Source: ALK Abello

Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first quarter of 2026 in the morning on Tuesday, 5 May 2026. Later on the same day, the company will host a presentation for...
20 avr. 2026 08h33 HE | Source: ALK Abello

ALK annoncerer positive fase 2-resultater for tablet til behandling af peanutallergi, som viser tidligt indsættende effekt

Intern viden ALLIANCE fase 2‑studiet demonstrerede proof‑of‑concept efter kun 6 måneders vedligeholdelsesbehandling i en bred patientgruppe bestående af både børn og voksne.Klar dosisafhængig og...
20 avr. 2026 08h33 HE | Source: ALK Abello

ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy

Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults.Clear...
15 avr. 2026 06h07 HE | Source: ALK Abello

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites,...
08 avr. 2026 16h37 HE | Source: ALK Abello

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): I henhold til artikel 19 i EU-forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende...
08 avr. 2026 16h37 HE | Source: ALK Abello

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
01 avr. 2026 04h05 HE | Source: ALK Abello

Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): I henhold til selskabets vederlagspolitik, som er vedtaget på selskabets ordinære generalforsamling den 16. marts 2026, og i tråd med selskabets sædvanlige...
01 avr. 2026 04h05 HE | Source: ALK Abello

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 16 March 2026 and in line with the company’s usual practice,...
31 mars 2026 03h01 HE | Source: ALK Abello

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis

Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...

Page précédente

Page suivante